RTR|TRT [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2014-10-22 18:36 (3856 d 19:54 ago) – Posting: # 13769
Views: 14,520

Hi Felipe,

I oppose our Master when he wrote:

Thus it isn't necessary to have two administrations of Test within each subject.

Correct, if you have only CVWR needed for scaling in mind. But – if CVWR<30% – FDA’s mixed-effects code fails sometimes in partial replicated studies (TRR|RRT|RTR) since the model is over-specifed. Either parameterize the covariance structure as FA0(1) – instead of TYPE=FA0(2) given in the guidance – or perform a fully replicated three-period design (RTR|TRT). This design seemingly con­verges always and additionally gives you information about your product.

Sample sizes for FDA’s RSABE (T/R 90%, 80% power):
CV%          20  30  40  50  80
───────────────────────────────
RTRT|TRTR    32  24  24  22  28
TRR|RRT|RTR  30  45  33  30  42
RTR|TRT      28  46  38  34  44


I would not recommend a four-period study (more blood draws / subjects, higher drop-out rate).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
142 visitors (0 registered, 142 guests [including 7 identified bots]).
Forum time: 14:30 CEST (Europe/Vienna)

Only dead fish go with the current.    Scuba divers' proverb

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5